A Quantitative Systems Pharmacology Approach to Infer Pathways Involved in Complex Disease Phenotypes

• Published in: Methods in molecular biology (Clifton, N.J.) Vol. 1787; p. 207
• Main Authors: Schurdak, Mark E, Pei, Fen, Lezon, Timothy R, Carlisle, Diane, Friedlander, Robert, Taylor, D Lansing, Stern, Andrew M
• Format: Journal Article
• Language: English
• Published: United States 2018
• Subjects: PHI; Heterogeneity; Precision medicine; Pittsburgh Heterogeneity Index; Chemogenomics; Huntington’s disease; Quantitative systems pharmacology; QSP
• ISSN: 1940-6029
• DOI: 10.1007/978-1-4939-7847-2_16

Designing effective therapeutic strategies for complex diseases such as cancer and neurodegeneration that involve tissue context-specific interactions among multiple gene products presents a major challenge for precision medicine. Safe and selective pharmacological modulation of individual molecular entities associated with a disease often fails to provide efficacy in the clinic. Thus, development of optimized therapeutic strategies for individual patients with complex diseases requires a more comprehensive, systems-level understanding of disease progression. Quantitative systems pharmacology (QSP) is an approach to drug discovery that integrates computational and experimental methods to understand the molecular pathogenesis of a disease at the systems level more completely. Described here is the chemogenomic component of QSP for the inference of biological pathways involved in the modulation of the disease phenotype. The approach involves testing sets of compounds of diverse mechanisms of action in a disease-relevant phenotypic assay, and using the mechanistic information known for the active compounds, to infer pathways and networks associated with the phenotype. The example used here is for monogenic Huntington's disease (HD), which due to the pleiotropic nature of the mutant phenotype has a complex pathogenesis. The overall approach, however, is applicable to any complex disease.